What is Celldex Therapeutics's G&A?

Celldex Therapeutics (CLDX) reported G&A of $11.45M in Q1 2026.

How has Celldex Therapeutics's G&A changed year-over-year?

Celldex Therapeutics's G&A increased by 5.8% year-over-year, from $10.82M to $11.45M.

What is the long-term trend for Celldex Therapeutics's G&A?

Over 4 years (2021 to 2025), Celldex Therapeutics's G&A has grown at a 20.9% compound annual growth rate (CAGR), from $20.49M to $43.84M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Celldex Therapeutics CLDX G&A

G&A at other companies

Nurix Therapeutics, Inc.NRIX

$14.61M+25.4%

Capricor TherapeuticsCAPR

$9.4M+54.9%

Dianthus TherapeuticsDNTH

$12.47M+69.9%

Immunovant, Inc.IMVT

$17.27M-14.4%

Kymera TherapeuticsKYMR

$20.36M+25.1%

Alumis Inc.ALMS

$18.61M-16.5%

Other financials

Income statement

See full

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Balance sheet

See full

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total equity$456.2M-35.1%

Total assets$511.3M-30.9%

Cash flow

See full

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Valuation

See full

Market cap$2.59B+75.2%

Enterprise value$2.55B+74.4%

P/S2,989.2×+2,794×

Profitability

See full

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Returns & leverage

See full

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Celldex Therapeutics's G&A?: Celldex Therapeutics (CLDX) reported G&A of $11.45M in Q1 2026.
How has Celldex Therapeutics's G&A changed year-over-year?: Celldex Therapeutics's G&A increased by 5.8% year-over-year, from $10.82M to $11.45M.
What is the long-term trend for Celldex Therapeutics's G&A?: Over 4 years (2021 to 2025), Celldex Therapeutics's G&A has grown at a 20.9% compound annual growth rate (CAGR), from $20.49M to $43.84M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.